GSK vs RMBS · P/E 13, $103.31B cap vs P/E 34, rev $707.6M
GlaxoSmithKline PLC ADR (GSK) versus Rambus Inc (RMBS) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Rambus Inc (RMBS) is a semiconductors company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported RMBS revenue for 2025-12-31 was $707.6M. Net income was $230.5M. Revenue was up 27.1% from 2024-12-31 to 2025-12-31. RMBS currently screens at market cap $7.08B and trailing P/E 34.5.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. RMBS currently screens at market cap $7.08B and trailing P/E 34.5.
Not investment advice. Open the GSK and RMBS stock pages for the full models.
Not investment advice.